Should I buy or sell Krystal Biotech stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks .

What is Krystal Biotech's stock price target for 2024?

9 analysts have issued 12-month price targets for Krystal Biotech's stock. Their KRYS share price targets range from $118.00 to $204.00. On average, they expect the company's share price to reach $164.22 in the next twelve months. This suggests a possible upside of 3.6% from the stock's current price. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts .

How have KRYS shares performed in 2024?

Krystal Biotech's stock was trading at $124.06 at the beginning of 2024. Since then, KRYS shares have increased by 27.8% and is now trading at $158.53. View the best growth stocks for 2024 here .

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our KRYS earnings forecast .

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its earnings results on Monday, February, 26th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.82. The company had revenue of $42.14 million for the quarter, compared to analyst estimates of $27.43 million. During the same period last year, the firm earned ($1.25) earnings per share.

What ETFs hold Krystal Biotech's stock?

ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD) , Franklin Genomic Advancements ETF (HELX) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Harbor Disruptive Innovation ETF (INNO) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) , SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC) .

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE) , Allena Pharmaceuticals (ALNA) , Gilead Sciences (GILD) , Sorrento Therapeutics (SRNE) , Corbus Pharmaceuticals (CRBP) , VBI Vaccines (vbiv) , Verastem (VSTM) , CRISPR Therapeutics (CRSP) , Editas Medicine (EDIT) and NVIDIA (NVDA) .

When did Krystal Biotech IPO?

Krystal Biotech (KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.56%), Hennion & Walsh Asset Management Inc. (0.12%) and Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Andrew C Orth, Daniel Janney , Dino A Rossi , Kathryn Romano , Krish S Krishnan and Suma Krishnan . View institutional ownership trends .

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:KRYS

Krystal Biotech (KRYS) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free KRYS Stock Alerts

$158.53

-5.44 (-3.32%)

(As of 04/19/2024 ET)

Compare

Today's Range: $155.91
▼
$164.53
50-Day Range: $108.01
▼
$180.42
52-Week Range: $82.09
▼
$189.97

Volume: 341,337 shs
Average Volume: 371,775 shs
Market Capitalization: $4.52 billion

P/E Ratio: 1,981.87
Dividend Yield: N/A
Price Target: $164.22

Get Krystal Biotech alerts:

Krystal Biotech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 3.6% Upside
$164.22 Price Target
Short Interest: Bearish
7.61% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: 0.67
Based on 7 Articles This Week
Insider Trading: Selling Shares
$6.54 M Sold Last Quarter
Proj. Earnings Growth: 109.52%
From $1.89 to $3.96 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.59 out of 5 stars

Medical Sector

252nd out of 918 stocks

Biological Products, Except Diagnostic Industry

35th out of 151 stocks

1.5

Analyst's Opinion

Consensus Rating
Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Krystal Biotech has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.61% of the outstanding shares of Krystal Biotech have been sold short.
Short Interest Ratio / Days to Cover
Krystal Biotech has a short interest ratio ("days to cover") of 5.5.
Change versus previous month
Short interest in Krystal Biotech has recently decreased by 3.12%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Krystal Biotech does not currently pay a dividend.
Dividend Growth
Krystal Biotech does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Krystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Krystal Biotech is -0.87.

2.6

News and Social Media Coverage

News Sentiment
Krystal Biotech has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Krystal Biotech this week, compared to 4 articles on an average week.
Search Interest
Only 3 people have searched for KRYS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,535,591.00 in company stock.
Percentage Held by Insiders
14.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Krystal Biotech are expected to grow by 109.52% in the coming year, from $1.89 to $3.96 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Krystal Biotech is 1,981.87, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 140.45.
Price to Earnings Ratio vs. Sector
The P/E ratio of Krystal Biotech is 1,981.87, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 215.55.
Price to Book Value per Share Ratio
Krystal Biotech has a P/B Ratio of 5.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Krystal Biotech Stock (NASDAQ:KRYS)

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

KRYS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KRYS Stock News Headlines

April 18, 2024 | msn.com

Century Real Estate raises ₹450 crore from Edelweiss to buy land and pay debts

April 17, 2024 | americanbankingnews.com

Krystal Biotech (NASDAQ:KRYS) Given Buy Rating at Stifel Nicolaus

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 15, 2024 | finance.yahoo.com

Recent 3.8% pullback isn't enough to hurt long-term Krystal Biotech (NASDAQ:KRYS) shareholders, they're still up 437% over 5 years

April 12, 2024 | msn.com

Karnataka 2nd PUC Result 2024 DECLARED: How to check Class 12 result at karresults.nic.in, other official website

April 12, 2024 | finance.yahoo.com

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

April 4, 2024 | tmcnet.com

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

April 4, 2024 | globenewswire.com

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 27, 2024 | investorplace.com

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

March 26, 2024 | markets.businessinsider.com

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

March 16, 2024 | finance.yahoo.com

KRYS Apr 2024 180.000 call

March 16, 2024 | finance.yahoo.com

KRYS Apr 2024 145.000 put

March 16, 2024 | finance.yahoo.com

KRYS Aug 2024 210.000 call

March 15, 2024 | bizjournals.com

These are the next generation of biotech superstars in the Bay Area

March 14, 2024 | finance.yahoo.com

KRYS Mar 2024 210.000 call

March 14, 2024 | finance.yahoo.com

KRYS May 2024 210.000 call

March 6, 2024 | msn.com

Krystal Biotech confirms cancellation from Cowen conference due to CEO sickness

March 4, 2024 | ca.finance.yahoo.com

KRYS May 2024 200.000 put

March 2, 2024 | finance.yahoo.com

Chief Accounting Officer Kathryn Romano Sells 5,000 Shares of Krystal Biotech Inc (KRYS)

March 1, 2024 | benzinga.com

$1000 Invested In This Stock 5 Years Ago Would Be Worth $7,400 Today

March 1, 2024 | fool.com

2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years

February 28, 2024 | seekingalpha.com

Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript

February 28, 2024 | finance.yahoo.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call Transcript

February 28, 2024 | markets.businessinsider.com

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

February 28, 2024 | globenewswire.com

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

February 27, 2024 | seekingalpha.com

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

See More Headlines

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:KRYS
CUSIP: N/A
CIK: 1711279
Web: www.krystalbio.com
Phone: (412) 586-5830
Fax: N/A
Employees: 229
Year Founded: 2017

Price Target and Rating

Average Stock Price Target: $164.22
High Stock Price Target: $204.00
Low Stock Price Target: $118.00
Potential Upside/Downside: +1.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.08
Trailing P/E Ratio: 2,022.88
Forward P/E Ratio: 85.61
P/E Growth: N/A
Net Income: $10.93 million
Net Margins: N/A
Pretax Margin: 25.44%
Return on Equity: -13.31%
Return on Assets: -12.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.76
Quick Ratio: 17.55

Sales & Book Value

Annual Sales: $50.70 million
Price / Sales: 90.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $27.60 per share
Price / Book: 5.86

Miscellaneous

Outstanding Shares: 28,510,000
Free Float: 24,494,000
Market Cap: $4.61 billion
Optionable: Optionable
Beta: 0.85

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Krish S. Krishnan M.B.A. (Age 59)
M.S., Founder, Chairman, President & CEO
Comp: $1.07M
Ms. Suma M. Krishnan (Age 59)
Founder, COO, President of R&D and Director
Comp: $789.92k
Ms. Kathryn A. Romano (Age 42)
Executive VP & Chief Accounting Officer
Comp: $528.87k
Mr. John Thomas
General Counsel & Corporate Secretary
Mr. John Karakkal
Vice President of North American Sales & Marketing
Ms. Christine Wilson
Head of U.S. Sales and Marketing
Mr. Josh Suskin
Director of Human Resources & Operations
Dr. Hubert C. Chen M.D. (Age 55)
Senior Vice President of Clinical Development
Mr. Laurent Goux
Senior VP & GM of Europe
Mr. Ram Kamineni
Senior Vice President of CMC & Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KRYS Stock Analysis - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings or view top-rated stocks.
What is Krystal Biotech's stock price target for 2024?: 9 analysts have issued 12-month price targets for Krystal Biotech's stock. Their KRYS share price targets range from $118.00 to $204.00. On average, they expect the company's share price to reach $164.22 in the next twelve months. This suggests a possible upside of 3.6% from the stock's current price.
View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts.
How have KRYS shares performed in 2024?: Krystal Biotech's stock was trading at $124.06 at the beginning of 2024. Since then, KRYS shares have increased by 27.8% and is now trading at $158.53.
View the best growth stocks for 2024 here.
When is Krystal Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our KRYS earnings forecast.
How were Krystal Biotech's earnings last quarter?: Krystal Biotech, Inc. (NASDAQ:KRYS) posted its earnings results on Monday, February, 26th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.82. The company had revenue of $42.14 million for the quarter, compared to analyst estimates of $27.43 million. During the same period last year, the firm earned ($1.25) earnings per share.
What ETFs hold Krystal Biotech's stock?: ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Disruptive Innovation ETF (INNO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).

What other stocks do shareholders of Krystal Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).
When did Krystal Biotech IPO?: Krystal Biotech (KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.
Who are Krystal Biotech's major shareholders?: Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.56%), Hennion & Walsh Asset Management Inc. (0.12%) and Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends.
How do I buy shares of Krystal Biotech?: Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRYS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Krystal Biotech (KRYS) Stock Price, News & Analysis

Krystal Biotech MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Krystal Biotech Stock (NASDAQ:KRYS)

KRYS Stock Price History

KRYS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

KRYS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™